Bausch Health Companies Inc (BHC)vsMerck & Company Inc (MRK)
BHC
Bausch Health Companies Inc
$5.86
-3.46%
HEALTHCARE · Cap: $2.40B
MRK
Merck & Company Inc
$144.85
+0.64%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 513% more annual revenue ($66.57B vs $10.85B). MRK leads profitability with a 4.8% profit margin vs -10.1%. BHC appears more attractively valued with a PEG of 0.01. BHC earns a higher WallStSmart Score of 70/100 (B).
BHC
Strong Buy70
out of 100
Grade: B
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BHC.
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$144.85
$62.01 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 44 in profit
Earnings expanding 70.4% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 27.2%
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Distress zone — elevated risk
Currently unprofitable
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BHC
The strongest argument for BHC centers on PEG Ratio, Return on Equity, EPS Growth. Revenue growth of 12.7% demonstrates continued momentum. PEG of 0.01 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : BHC
The primary concerns for BHC are Altman Z-Score, Profit Margin.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
BHC profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
BHC carries more volatility with a beta of 0.37 — expect wider price swings.
BHC is growing revenue faster at 12.7% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
BHC scores higher overall (70/100 vs 36/100) and 12.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bausch Health Companies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Bausch Health Companies Inc. develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology and dermatology. The company is headquartered in Laval, Canada.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?